8-KCorporate ChangesOther EventsExhibits & Filings

BIOGEN INC. 8-K Report, Bylaw Amendment (Oct 3, 2005)

Filed October 3, 2005For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) filed an 8-K on October 3, 2005, to report two key events. First, the Board of Directors approved an amendment and restatement of the Company's Bylaws. These changes aim to modernize corporate governance, align with Delaware law, and clarify existing provisions. Notable amendments include an advance notice requirement for director nominations and stockholder proposals, the Board's retained right to fill director vacancies, authorization for uncertificated securities, and mandatory indemnification and expense advancement for officers. Second, and of significant investor interest, Biogen Idec and Elan Corporation jointly announced on September 26, 2005, the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for TYSABRI® (natalizumab) for the treatment of multiple sclerosis. This submission marks a critical step in the potential re-introduction of TYSABRI® to the market, which has been a key focus for the company and its investors.

Key Highlights

  • 1Biogen Idec's Board of Directors approved updated Bylaws to conform with modern corporate practices and Delaware law.
  • 2Key bylaw changes include advance notice requirements for director nominations and stockholder proposals.
  • 3The Board will retain the right to fill director vacancies, enhancing governance flexibility.
  • 4The company and Elan Corporation submitted a supplemental Biologics License Application (sBLA) for TYSABRI® (natalizumab) to the FDA.
  • 5The sBLA is for the treatment of multiple sclerosis, indicating a potential path for TYSABRI®'s re-introduction.
  • 6The press release detailing the TYSABRI® submission is incorporated by reference and filed as an exhibit.

Frequently Asked Questions

The primary purpose of the amended and restated Bylaws is to bring the Company's governing documents into conformance with modern corporate governance practices and changes in the Delaware General Corporation Law, as well as to reconcile prior amendments and eliminate inconsistencies.

For shareholders, the most significant changes include the imposition of an advance notice requirement for nominating candidates for director and for submitting proposals for action at annual meetings. This requires shareholders to notify the company in advance of such actions.

The sBLA submission to the FDA for TYSABRI® (natalizumab) is a critical step towards potentially regaining market approval for the drug for the treatment of multiple sclerosis. This submission indicates progress in addressing any prior regulatory concerns and aims to demonstrate the drug's safety and efficacy for this indication.

Elan Corporation, plc is a partner of Biogen Idec in the development and potential commercialization of TYSABRI®. The joint press release and the sBLA submission highlight their collaborative effort in bringing TYSABRI® to market for multiple sclerosis patients.